Record Details

Role of biosimilar pegfilgrastim in the treatment of febrile neutropenia: A Mini Review

NOPR - NISCAIR Online Periodicals Repository

View Archive Info
 
 
Field Value
 
Title Role of biosimilar pegfilgrastim in the treatment of febrile neutropenia: A Mini Review
 
Creator Shahab, Shania
S, Ahmad
 
Subject Adverse events
Biosimilars
Chemotherapy-induced
Cost-effectiveness
Febrile neutropenia
GCSFs, Pegfilgrastim
Pharmacodynamic and pharmacokinetic profiles
Regulatory approvals
Savings, Therapeutics
 
Description 7-15
Biologics have no true generics due to their complex nature but biosimilars offer a hopeful alternative. Biosimilars are similar to
biologics as tested with comparable safety and efficacy profiles to the reference product. With more cancer patients needing
extensive chemotherapy, life threatening complications like febrile neutropenia (FN) can be fatal. FN is a medical condition
characterized by fever and a dangerously low count of neutrophils; a type of white blood cell crucial for fighting infections.
Pegfilgrastim, a modified long-lasting form of the medication filgrastim, has helped patients recover without comprising their active
chemotherapy regimens. Yet, for many cancer patients, the expenses associated with essential treatments persist as a significant
challenge, leaving limited resources available to address the accompanying adverse effects. Biosimilars to pegfilgrastim can
contribute to cost-savings, increase in accessibility and variability. This article delves into the fundamental advantages of
biosimilars comparing financial benefits and availability with special reference to biochemistry, pharmacology, and therapeutic
roles of pegfilgrastim in FN. It also undertakes the task of evaluating and synthesizing the safety and efficacy profiles of
pegfilgrastim biosimilars, encompassing those both available and pending approval from the U.S. Food and Drug Administration. It
provides hope and benefits for patients, clinicians, and healthcare organizations in the treatment of FN. Thus, we conclude that
biosimilars to pegfilgrastim are by-and-large comparable in regard to pharmacodynamic and pharmacokinetic profiles to the
reference products with no significant differences in safety and efficacy while treating FN.
 
Date 2024-01-12T11:48:21Z
2024-01-12T11:48:21Z
2024-01
 
Type Article
 
Identifier 0975-0959 (Online); 0301-1208 (Print)
http://nopr.niscpr.res.in/handle/123456789/63195
https://doi.org/10.56042/ijbb.v61i1.6830
 
Language en
 
Publisher NIScPR-CSIR, India
 
Source IJBB Vol.61(01) [January 2024]